Amedeo Smart

Free Medical Literature Service



Ovarian Neoplasms

  Free Subscription

Articles published in
Anticancer Drugs
    September 2021
  1. ROSE PG, Yao M, Chambers LM, Mahdi H, et al
    PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.
    Anticancer Drugs. 2021 Sep 13. pii: 00001813-900000000-98269.
    >> Share

    August 2021
  2. PARK GB, Jeong JY, Choi S, Yoon YS, et al
    Glucose deprivation enhances resistance to paclitaxel via ELAVL2/4-mediated modification of glycolysis in ovarian cancer cells.
    Anticancer Drugs. 2021 Aug 19. pii: 00001813-900000000-98297.
    >> Share

    July 2021
  3. SUN S, Sun W, Xiang Q, Yang C, et al
    Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report.
    Anticancer Drugs. 2021 Jul 30. pii: 00001813-900000000-98352.
    >> Share

    March 2021
  4. WEI S, Qi L, Wang L
    Overexpression of circ_CELSR1 facilitates paclitaxel resistance of ovarian cancer by regulating miR-149-5p/SIK2 axis.
    Anticancer Drugs. 2021 Mar 16. pii: 00001813-900000000-98432.
    >> Share

    January 2021
  5. ZHANG W, Huang X, Shi J
    EZH2-mediated lncRNA ABHD11-AS1 promoter regulates the progression of ovarian cancer by targeting miR-133a-3p.
    Anticancer Drugs. 2021 Jan 22. pii: 00001813-900000000-98466.
    >> Share

    June 2020
  6. HU H, Zhu S, Tong Y, Huang G, et al
    Antitumor activity of triptolide in SKOV3 cells and SKOV3/DDP in vivo and in vitro.
    Anticancer Drugs. 2020;31:483-491.
    >> Share

    November 2019
  7. GUO Q, Yang Q, Li J, Liu G, et al
    Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening.
    Anticancer Drugs. 2019 Nov 15. doi: 10.1097/CAD.0000000000000858.
    >> Share

    September 2019
  8. MORI KM, Giuliano PD, Lopez KL, King MM, et al
    Pronounced clinical response following the oncolytic vaccinia virus GL-ONC1 and chemotherapy in a heavily pretreated ovarian cancer patient.
    Anticancer Drugs. 2019 Sep 16. doi: 10.1097/CAD.0000000000000836.
    >> Share

  9. HUANG YS, Wang TX, Lin XM, Wang H, et al
    Antitumor effect of a short peptide on p53-null SKOV3 ovarian cancer cells.
    Anticancer Drugs. 2019 Sep 9. doi: 10.1097/CAD.0000000000000830.
    >> Share

    July 2019
  10. VILLA M, Attianese D, Petracchini M, Ferrero A, et al
    Oral metronomic cyclophosphamide in advanced ovarian cancer: long-lasting clinical response in an elderly frailty patient.
    Anticancer Drugs. 2019 Jul 11. doi: 10.1097/CAD.0000000000000815.
    >> Share

    April 2019
  11. ROMERO I, Mallol P, Santaballa A, Del Campo JM, et al
    Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer.
    Anticancer Drugs. 2019 Apr 18. doi: 10.1097/CAD.0000000000000794.
    >> Share

  12. LIU L, Liu P, Liang Z, Li R, et al
    Poly (ADP-ribose) polymerase inhibitors combined with other small-molecular compounds for the treatment of ovarian cancer.
    Anticancer Drugs. 2019 Apr 16. doi: 10.1097/CAD.0000000000000793.
    >> Share

    March 2019
  13. FAN M, Li C, He P, Fu Y, et al
    Knockdown of long noncoding RNA-taurine-upregulated gene 1 inhibits tumor angiogenesis in ovarian cancer by regulating leucine-rich alpha-2-glycoprotein-1.
    Anticancer Drugs. 2019 Mar 20. doi: 10.1097/CAD.0000000000000734.
    >> Share

    January 2019
  14. LIU Y, Zhou H, Yi T, Wang H, et al
    Pyrimethamine exerts significant antitumor effects on human ovarian cancer cells both in vitro and in vivo.
    Anticancer Drugs. 2019 Jan 5. doi: 10.1097/CAD.0000000000000740.
    >> Share

    September 2018
  15. SONG MM, Makena MR, Hindle A, Koneru B, et al
    Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia.
    Anticancer Drugs. 2018 Sep 27. doi: 10.1097/CAD.0000000000000696.
    >> Share

    November 2017
  16. LV KT, Gao LJ, Hua X, Li F, et al
    The role of the globular heads of the C1q receptor in paclitaxel-induced human ovarian cancer cells apoptosis by a mitochondria-dependent pathway.
    Anticancer Drugs. 2017 Nov 23. doi: 10.1097/CAD.0000000000000567.
    >> Share

    September 2017
  17. ASSI T, Kourie HR, El Rassy E, Moussa T, et al
    Response of an ovarian granulosa cell tumor with everolimus and exemestane after initial response to letrozole.
    Anticancer Drugs. 2017;28:931-933.
    >> Share

    August 2017
  18. REEVES PM, Abbaslou MA, Kools FRW, Poznansky MC, et al
    CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth.
    Anticancer Drugs. 2017 Aug 16. doi: 10.1097/CAD.0000000000000518.
    >> Share

    July 2017
  19. BORASKA JELAVIC T, Boban T, Brcic L, Vrdoljak E, et al
    Is macrocytosis a potential biomarker of the efficacy of dose-dense paclitaxel-carboplatin combination therapy in patients with epithelial ovarian cancer?
    Anticancer Drugs. 2017 Jul 3. doi: 10.1097/CAD.0000000000000538.
    >> Share

    May 2017
  20. PENDLEBURY A, DeBernardo R, Rose PG
    Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600 mg/m2 in recurrent ovarian cancer.
    Anticancer Drugs. 2017 May 24. doi: 10.1097/CAD.0000000000000521.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016